Can alendronate improve bone density in the hip?

Alendronate ranked highest for improving Bone Mineral Density in one hip area in a review of 41 studies. Alendronate belongs to Bisphosphonates, medicines that slow bone breakdown. The review compared medicines for osteoporosis after menopause. Osteoporosis means bones become weak and more likely to break. The women studied were all aged 40 or older. The 41 studies came from 17 countries. Study sizes ranged from 22 to 7,868 women. Follow-up lasted from 1 to 60 months. Of these studies, 28 examined medicines in this group. The standout result concerned Bone Mineral Density at the trochanter. This is a part of the hip where muscles attach. Alendronate ranked highest for improving this measure. Another medicine in the same group, ibandronate, ranked highest for lowering a marker of bone breakdown. That difference matters: the leading medicine depended on what was measured. The authors suggest these medicines may help because they stay in bone. Their lasting effects could help preserve bone in this load-bearing area. That is a proposed explanation, not proof of why the ranking occurred. The supplied results do not give the size of alendronate’s benefit. A top ranking alone also does not show how many fractures it prevents. It should not be read as best for every person or outcome. For BioSocial members, the useful takeaway is to keep scan details together. The exact medicine, scan location, dates, and changes in your numbers add context. Sharing those details can make community comparisons more useful than rankings alone. What changes have you seen in your scan numbers over time, and which medicine were you tracking?